Abstract
Background: During the eleven months of the novel SARS-CoV-2 disease (COVID-19) outbreak in China and its global spread, there is a remarkable understanding of its epidemiology, pathobiology, and clinical management strategies. While countering a heavy toll on health and the economy, world’s regional authorities are enforcing safety guidelines and providing patient care. Currently, there is no globally approved treatment or intervention for COVID-19.
Methods: A structured online literature search for peer-reviewed articles was conducted on PubMed, Europe PMC, Google, WHO, CDC, FDA, and ClinicalTrials portals, using phrases such as COVID-19 treatment and intervention, COVID-19 drugs and COVID-19 vaccines.
Results: Analysis of the retrieved data showed that as a part of ‘Solidarity Clinical Trials’, hundreds of treatment and intervention strategies, including antiviral drugs, cytokine antagonists, convalescent plasma therapy, and vaccine candidates, have been registered worldwide. While remdesivir, the anti- Ebola virus drug, has been approved as an ‘emergency use’ drug in the USA, favipiravir, the anti-flu drug, has been recently approved in Russia. Tocilizumab and sarilumab, the cytokine (IL-6) antagonists, have entered Phase-II/III clinical trials in hospitalized COVID-19 patients. Among the leading vaccine candidates, Phase-III clinical trial results of Moderna, Pfizer and Oxford vaccines seem to be game changers for COVID19.
Conclusion: The world health authorities have strongly and quickly responded to the COVID-19 pandemic. Nonetheless, world bodies must unite in combating this health crisis by developing cost-effective drugs and vaccines and making them accessible to resource-poor countries.
Keywords: SARS-CoV-2, COVID-19, antiviral, chloroquine, remdesivir, vaccine.
Graphical Abstract
[http://dx.doi.org/10.3892/wasj.2020.59]]
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[http://dx.doi.org/10.1016/S2589-7500(20)30086-8] [PMID: 32363333]
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]
[http://dx.doi.org/10.1002/jmv.25758] [PMID: 32167166]
[http://dx.doi.org/10.1007/s13337-020-00571-5] [PMID: 32206694]
[http://dx.doi.org/10.1016/j.cell.2020.02.058]]
[http://dx.doi.org/10.1186/s12985-019-1182-0] [PMID: 31133031]
[http://dx.doi.org/10.1086/422040] [PMID: 15216476]
[http://dx.doi.org/10.1148/radiol.2020201160] [PMID: 32216717]
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[http://dx.doi.org/10.1053/j.gastro.2020.02.054] [PMID: 32142785]
[http://dx.doi.org/10.18063/ghl.v2i1.250]]
[http://dx.doi.org/10.2217/fvl-2020-0065]
[http://dx.doi.org/10.1016/j.bbrc.2020.03.044] [PMID: 32199615]
[http://dx.doi.org/10.1007/s00392-020-01626-9] [PMID: 32161990]
[http://dx.doi.org/10.1016/j.ajem.2020.04.048] [PMID: 32317203]
[http://dx.doi.org/10.1002/jmv.25681] [PMID: 31967327]
[http://dx.doi.org/10.1016/j.coviro.2012.04.004] [PMID: 22572391]
[http://dx.doi.org/10.1016/j.jaci.2020.04.027]]
[http://dx.doi.org/10.1099/vir.0.055533-0] [PMID: 24077366]
[http://dx.doi.org/10.1073/pnas.2005615117] [PMID: 32350134]
[http://dx.doi.org/10.1038/s41421-020-0168-9] [PMID: 32377375]
[http://dx.doi.org/10.1038/s41392-020-0148-4] [PMID: 32296069]
[http://dx.doi.org/10.1101/2020.04.07.20056424]
[http://dx.doi.org/10.1101/2020.04.02.20047050]]
[http://dx.doi.org/10.1056/NEJMoa2012410] [PMID: 32379955]
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[http://dx.doi.org/10.1056/NEJMoa2021436]] [PMID: 32678530]
[http://dx.doi.org/10.1182/blood.2020006288] [PMID: 32302379]
[http://dx.doi.org/10.1016/S2665-9913(20)30127-2]]
[http://dx.doi.org/10.1038/d41573-020-00073-5] [PMID: 32273591]
[http://dx.doi.org/10.1056/NEJMoa2022483] [PMID: 32663912]
[http://dx.doi.org/10.1101/2020.06.30.20142570]]
[http://dx.doi.org/10.1016/S0140-6736(20)31604-4] [PMID: 32702298]
[http://dx.doi.org/10.1002/wrna.32] [PMID: 21956969]
[http://dx.doi.org/10.1016/S0140-6736(20)31208-3] [PMID: 32450106]
[http://dx.doi.org/10.1126/science.368.6492.692]